{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:08:54Z","timestamp":1791356934296,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tissue architecture and cell\u2013extracellular matrix (cell\u2013ECM) interaction determine the organ specificity; however, the influences of these factors on anticancer drugs preclinical studies are highly neglected. For considering such aspects, three-dimensional (3D) cell culture models are relevant tools for accurate analysis of cellular responses to chemotherapy. Here we compared the MCF-7 breast cancer cells responses to cisplatin in traditional two-dimensional (2D) and in 3D-reconstituted basement membrane (3D-rBM) cell culture models. The results showed a substantial increase of cisplatin resistance mediated by 3D microenvironment. This phenotype was independent of p53 status and autophagy activity and was also observed for other cellular models, including lung cancer cells. Such strong decrease on cellular sensitivity was not due to differences on drug-induced DNA damage, since similar levels of \u03b3-H2AX and cisplatin\u2013DNA adducts were detected under both conditions. However, the processing of these cisplatin-induced DNA lesions was very different in 2D and 3D cultures. Unlike cells in monolayer, cisplatin-induced DNA damage is persistent in 3D-cultured cells, which, consequently, led to high senescence induction. Moreover, only 3D-cultured cells were able to progress through S cell cycle phase, with unaffected replication fork progression, due to the upregulation of translesion (TLS) DNA polymerase expression and activation of the ATR-Chk1 pathway. Co-treatment with VE-821, a pharmacological inhibitor of ATR, blocked the 3D-mediated changes on cisplatin response, including low sensitivity and high TLS capacity. In addition, ATR inhibition also reverted induction of REV3L by cisplatin treatment. By using REV3L-deficient cells, we showed that this TLS DNA polymerase is essential for the cisplatin sensitization effect mediated by VE-821. Altogether, our results demonstrate that 3D-cell architecture-associated resistance to cisplatin is due to an efficient induction of REV3L and TLS, dependent of ATR. Thus co-treatment with ATR inhibitors might be a promising strategy for enhancement of cisplatin treatment efficiency in breast cancer patients.<\/jats:p>","DOI":"10.1038\/s41419-019-1689-8","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T10:03:11Z","timestamp":1560333791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation"],"prefix":"10.1038","volume":"10","author":[{"given":"Luciana Rodrigues","family":"Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa Ribeiro Reily","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davi Jardim","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Zen Petisco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Sarti","family":"Kinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bruni-Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Frederico Martins","family":"Menck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1689_CR2","first-page":"2","volume":"16","author":"MJ Bissell","year":"2007","unstructured":"Bissell, M. J. Architecture is the message: the role of extracellular matrix and 3-D structure in tissue-specific gene expression and breast cancer. Pezcoller Found J. 16, 2\u201317 (2007).","journal-title":"Pezcoller Found J."},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2015.09.012","volume":"35","author":"M Giussani","year":"2015","unstructured":"Giussani, M., Merlino, G., Cappelletti, V., Tagliabue, E. & Daidone, M. G. Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression. Semin. Cancer Biol. 35, 3\u201310 (2015).","journal-title":"Semin. Cancer Biol."},{"key":"1689_CR4","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1038\/onc.2014.461","volume":"34","author":"LR Gomes","year":"2015","unstructured":"Gomes, L. R., Vessoni, A. T. & Menck, C. F. Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy. Oncogene 34, 5329\u20135340 (2015).","journal-title":"Oncogene"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1242\/jcs.079509","volume":"125","author":"BM Baker","year":"2012","unstructured":"Baker, B. M. & Chen, C. S. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J. Cell Sci. 125, 3015\u20133024 (2012).","journal-title":"J. Cell Sci."},{"key":"1689_CR6","doi-asserted-by":"crossref","first-page":"201367","DOI":"10.4061\/2010\/201367","volume":"2010","author":"A Basu","year":"2010","unstructured":"Basu, A. & Krishnamurthy, S. Cellular responses to Cisplatin-induced DNA damage. J. Nucleic Acids 2010, 201367 (2010).","journal-title":"J. Nucleic Acids"},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1756-9966-30-91","volume":"30","author":"N Eckstein","year":"2011","unstructured":"Eckstein, N. Platinum resistance in breast and ovarian cancer cell lines. J. Exp. Clin. Cancer Res. 30, 91 (2011).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573\u2013584 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"1689_CR9","volume":"73","author":"CRR Rocha","year":"2018","unstructured":"Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B. & Menck, C. F. M. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo) 73, e478s (2018).","journal-title":"Clinics (Sao Paulo)"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 149, 124\u2013138 (2015).","journal-title":"Pharmacol. Ther."},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/onc.2010.624","volume":"30","author":"N Sangster-Guity","year":"2011","unstructured":"Sangster-Guity, N., Conrad, B. H., Papadopoulos, N. & Bunz, F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 30, 2526\u20132533 (2011).","journal-title":"Oncogene"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nsmb.2295","volume":"19","author":"A Ummat","year":"2012","unstructured":"Ummat, A. et al. Structural basis for cisplatin DNA damage tolerance by human polymerase \u03b7 during cancer chemotherapy. Nat. Struct. Mol. Biol. 19, 628\u2013632 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1124\/mol.111.076828","volume":"81","author":"S Sharma","year":"2012","unstructured":"Sharma, S., Shah, N. A., Joiner, A. M., Roberts, K. H. & Canman, C. E. DNA polymerase \u03b6 is a major determinant of resistance to platinum-based chemotherapeutic agents. Mol. Pharmacol. 81, 778\u2013787 (2012).","journal-title":"Mol. Pharmacol."},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth1015","volume":"4","author":"GY Lee","year":"2007","unstructured":"Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods. 4, 359\u2013365 (2007).","journal-title":"Nat. Methods."},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1101\/gad.452308","volume":"22","author":"LI Toledo","year":"2008","unstructured":"Toledo, L. I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297\u2013302 (2008).","journal-title":"Genes Dev."},{"key":"1689_CR16","first-page":"2705","volume":"63","author":"IB Roninson","year":"2003","unstructured":"Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705\u20132715 (2003).","journal-title":"Cancer Res."},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"10411","DOI":"10.1074\/jbc.M110.210989","volume":"286","author":"N Pabla","year":"2011","unstructured":"Pabla, N., Ma, Z., McIlhatton, M. A., Fishel, R. & Dong, Z. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J. Biol. Chem. 286, 10411\u201310418 (2011).","journal-title":"J. Biol. Chem."},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1242\/jcs.169730","volume":"128","author":"P Awasthi","year":"2015","unstructured":"Awasthi, P., Foiani, M. & Kumar, A. ATM and ATR signaling at a glance. J. Cell Sci. 128, 4255\u20134262 (2015).","journal-title":"J. Cell Sci."},{"key":"1689_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125482","volume":"10","author":"KN Mohni","year":"2015","unstructured":"Mohni, K. N. et al. A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments. PLoS ONE 10, e0125482 (2015).","journal-title":"PLoS ONE"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1158\/0008-5472.CAN-17-2056","volume":"77","author":"SE Jones","year":"2017","unstructured":"Jones, S. E. et al. ATR is a therapeutic target in synovial sarcoma. Cancer Res. 77, 7014\u20137026 (2017).","journal-title":"Cancer Res."},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/15384101.2017.1404206","volume":"17","author":"N Song","year":"2018","unstructured":"Song, N. et al. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage. Cell Cycle 17, 595\u2013604 (2018).","journal-title":"Cell Cycle"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"32396","DOI":"10.18632\/oncotarget.6136","volume":"6","author":"FK Middleton","year":"2015","unstructured":"Middleton, F. K. et al. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 6, 32396\u201332409 (2015).","journal-title":"Oncotarget"},{"key":"1689_CR24","first-page":"4899","volume":"62","author":"T Furuta","year":"2002","unstructured":"Furuta, T. et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62, 4899\u20134902 (2002).","journal-title":"Cancer Res."},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1590\/S1415-47572014000200008","volume":"37","author":"CF Menck","year":"2014","unstructured":"Menck, C. F. & Munford, V. DNA repair diseases: what do they tell us about cancer and aging? Genet. Mol. Biol. 37, 220\u2013233 (2014).","journal-title":"Genet. Mol. Biol."},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"E4777","DOI":"10.1073\/pnas.1804493115","volume":"115","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues. Proc. Natl Acad. Sci. USA 115, E4777\u2013E4785 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1016\/j.yexcr.2007.04.022","volume":"313","author":"J Le Beyec","year":"2007","unstructured":"Le Beyec, J. et al. Cell shape regulates global histone acetylation in human mammary epithelial cells. Exp. Cell Res. 313, 3066\u20133075 (2007).","journal-title":"Exp. Cell Res."},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.celrep.2017.05.050","volume":"19","author":"APZP Fiore","year":"2017","unstructured":"Fiore, A. P. Z. P. et al. Laminin-111 and the level of nuclear actin regulate epithelial quiescence via Exportin-6. Cell Rep. 19, 2102\u20132115 (2017).","journal-title":"Cell Rep."},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ccell.2016.09.015","volume":"30","author":"S Llanos","year":"2016","unstructured":"Llanos, S. & Serrano, M. Senescence and cancer: in the name of immunosuppression. Cancer Cell 30, 507\u2013508 (2016).","journal-title":"Cancer Cell"},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.trecan.2016.10.001","volume":"2","author":"SG Rao","year":"2016","unstructured":"Rao, S. G. & Jackson, J. G. SASP: tumor suppressor or promoter? Yes! Trends Cancer 2, 676\u2013687 (2016).","journal-title":"Trends Cancer"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"17049","DOI":"10.1038\/cddiscovery.2017.49","volume":"3","author":"L Yang","year":"2017","unstructured":"Yang, L., Fang, J. & Chen, J. Tumor cell senescence response produces aggressive variants. Cell Death Discov. 3, 17049 (2017).","journal-title":"Cell Death Discov."},{"key":"1689_CR32","first-page":"14","volume":"1865","author":"MK Ruhland","year":"2016","unstructured":"Ruhland, M. K., Coussens, L. M. & Stewart, S. A. Senescence and cancer: an evolving inflammatory paradox. Biochim. Biophys. Acta 1865, 14\u201322 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1091\/mbc.E16-06-0440","volume":"27","author":"MJ Bissell","year":"2016","unstructured":"Bissell, M. J. Thinking in three dimensions: discovering reciprocal signaling between the extracellular matrix and nucleus and the wisdom of microenvironment and tissue architecture. Mol. Biol. Cell. 27, 3205\u20133209 (2016).","journal-title":"Mol. Biol. Cell."},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1215\/15228517-2009-015","volume":"11","author":"H Wang","year":"2009","unstructured":"Wang, H. et al. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol. 11, 790\u2013802 (2009).","journal-title":"Neuro Oncol."},{"key":"1689_CR35","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3892\/or.2015.4121","volume":"34","author":"W Wang","year":"2015","unstructured":"Wang, W. et al. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. Oncol. Rep. 34, 1460\u20131468 (2015).","journal-title":"Oncol. Rep."},{"key":"1689_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120334","volume":"10","author":"L Yang","year":"2015","unstructured":"Yang, L. et al. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. PLoS ONE 10, e0120334 (2015).","journal-title":"PLoS ONE"},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364\u2013378 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"1689_CR38","first-page":"2275","volume":"23","author":"EM Yazlovitskaya","year":"2003","unstructured":"Yazlovitskaya, E. M. & Persons, D. L. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res. 23, 2275\u20132279 (2003).","journal-title":"Anticancer Res."},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall, A. B. et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5, 5674\u20135685 (2014).","journal-title":"Oncotarget"},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz, L. M. & Zou, L. Molecular pathways: targeting ATR in cancer therapy. Clin. Cancer Res. 21, 4780\u20134785 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.canlet.2011.09.019","volume":"314","author":"MC Moraes","year":"2012","unstructured":"Moraes, M. C. et al. Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions. Cancer Lett. 314, 108\u2013118 (2012).","journal-title":"Cancer Lett."},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.dnarep.2013.12.005","volume":"14","author":"A Quinet","year":"2014","unstructured":"Quinet, A. et al. Gap-filling and bypass at the replication fork are both active mechanisms for tolerance of low-dose ultraviolet-induced DNA damage in the human genome. DNA Repair (Amst). 14, 27\u201338 (2014).","journal-title":"DNA Repair (Amst)."},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109\u20131112 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1689_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies, J. et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7, e51862 (2012).","journal-title":"PLoS ONE"},{"key":"1689_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/jpi.12293","volume":"60","author":"GS Kinker","year":"2016","unstructured":"Kinker, G. S. et al. Melatonergic system-based two-gene index is prognostic in human gliomas. J. Pineal Res. 60, 84\u201394 (2016).","journal-title":"J. Pineal Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1689-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T16:16:34Z","timestamp":1721405794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1689-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,12]]},"assertion":[{"value":"14 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}